From DCAT Value Chain Insights (VCI)
Biogen has appointed Michel Vounatsos as executive vice president and chief commercial officer, effective April 18, 2016. He will oversee the development and execution of Biogen’s global commercial strategy, with a focus on the continued growth of Biogen’s product portfolio and the development of the commercial infrastructure and approach to support the company’s key pipeline assets. He will report to George Scangos, Ph.D., chief executive officer, and will be a member of the Biogen management team.
Mr. Vounatsos comes to Biogen after a 20 year career at Merck, where he most recently served as president, Primary Care Business Line and Merck Customer Centricity. Prior to this role, he held leadership positions at Merck across Europe and in China.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription